Testing combinations of three study drugs in healthy volunteers
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This trial tests how safe and tolerable three different study drugs (SION-451, SION-2222, and SION-109) are when taken together in healthy adults. The goal is to find a good dose combination for future studies in people with cystic fibrosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old
- You weigh at least 99 pounds (45 kg) and have a body mass index (BMI) between 18 and 32
- You can avoid alcohol, caffeine, smoking, and nicotine for 3 days before the study starts and for the whole study
- You can avoid broccoli, cauliflower, grilled meats, and poppy seeds for 2 days before each dose and during the study
- You are generally healthy without any major ongoing medical conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether people with cystic fibrosis who are already on a triple combination CFTR modulator can stay on their treatment without interruptions or problems. It aims to make sure everyone gets the best, most consistent treatment for their CF.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
This study tests new treatments for cystic fibrosis in people who cannot take or choose not to take current CFTR modulators. It aims to find better options for managing CF.
This early-phase study tests how different doses of an inhaled medicine (amphotericin B) work and are tolerated. It includes healthy adults and people with cystic fibrosis (CF) to see if the dose schedule is safe and potentially beneficial.
This Phase 2 trial tests 4D-710 to improve lung health in adults with cystic fibrosis who either cannot take CFTR modulator medicines or are not doing well enough on them. You may be eligible if you have moderate lung function and stable oxygen levels, and you meet other safety and health requirements.
This trial tests a new drug called SPL84 for people with cystic fibrosis who have a specific gene mutation (3849+10kb C->T). It aims to see if the drug is safe and can improve lung function. The study has two paths: one for people not taking certain CF drugs, and one for those who are already on Trikafta or Alyftrek.
Hear when a new Cystic Fibrosis (CF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.